{
    "ticker": "NOVVW",
    "name": "Novavax, Inc.",
    "description": "Novavax, Inc. is a biotechnology company dedicated to developing and commercializing innovative vaccines to prevent serious infectious diseases. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax has focused its efforts on creating vaccines for a variety of viral infectious diseases, including influenza, COVID-19, and RSV (respiratory syncytial virus). With a robust pipeline, the company employs its proprietary nanoparticle technology to produce vaccines that are safe and effective. Novavax's COVID-19 vaccine, NVX-CoV2373, has received Emergency Use Authorization in numerous countries and is integral to global vaccination efforts against the pandemic. The company is committed to addressing unmet medical needs and improving public health through its research and development activities. Novavax collaborates with various governmental and non-governmental organizations to enhance vaccine accessibility and distribution, aiming to contribute to global health security. With a strong focus on innovation, Novavax continues to explore new vaccine candidates and technologies, striving to be at the forefront of vaccine development.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Gaithersburg, Maryland, USA",
    "founded": "1987",
    "website": "https://www.novavax.com",
    "ceo": "Stanley C. Erck",
    "social_media": {
        "twitter": "https://twitter.com/novavax",
        "linkedin": "https://www.linkedin.com/company/novavax/"
    },
    "investor_relations": "https://investors.novavax.com",
    "key_executives": [
        {
            "name": "Stanley C. Erck",
            "position": "CEO"
        },
        {
            "name": "Gregory M. Glenn",
            "position": "President of Research and Development"
        }
    ],
    "product_categories": [
        {
            "category": "Vaccines",
            "products": [
                "NVX-CoV2373 (COVID-19)",
                "NanoFlu"
            ]
        }
    ],
    "seo": {
        "meta_title": "Novavax, Inc. | Innovative Vaccines for Infectious Diseases",
        "meta_description": "Discover Novavax, Inc., a leader in vaccine development for serious infectious diseases, including COVID-19. Learn about their innovative technologies and commitment to public health.",
        "keywords": [
            "Novavax",
            "Vaccines",
            "COVID-19 Vaccine",
            "Biotechnology",
            "Infectious Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Novavax known for?",
            "answer": "Novavax is known for developing innovative vaccines to prevent serious infectious diseases, including COVID-19."
        },
        {
            "question": "Who is the CEO of Novavax?",
            "answer": "Stanley C. Erck is the CEO of Novavax, Inc."
        },
        {
            "question": "Where is Novavax headquartered?",
            "answer": "Novavax is headquartered in Gaithersburg, Maryland, USA."
        },
        {
            "question": "What are Novavax's main products?",
            "answer": "Novavax's main products include NVX-CoV2373, a COVID-19 vaccine, and a seasonal flu vaccine known as NanoFlu."
        },
        {
            "question": "When was Novavax founded?",
            "answer": "Novavax was founded in 1987."
        }
    ],
    "competitors": [
        "MRNA",
        "PFE",
        "JNJ",
        "AZN"
    ],
    "related_stocks": [
        "GILD",
        "ABBV",
        "AMGN",
        "VRTX"
    ]
}